Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Getinge ( ($SE:GETI.B) ) has provided an update.
Getinge reported modest organic growth in the first quarter of 2026, with order intake up 3.9% and net sales edging 0.8% higher despite a sharp negative currency effect that drove a 10.5% reported sales decline. Performance was mixed across business areas, as Acute Care Therapies suffered from lower ventilator demand after last year’s consolidation-driven spike, while ECLS consumables and recurring revenues held up well and capital goods sales weakened.
Life Science delivered standout organic sales growth of 16%, led by Sterile Transfer, and Surgical Workflows achieved double-digit order intake growth across all product categories, particularly U.S. operating room equipment. Regionally, EMEA posted solid organic gains, offset by declines in the Americas and APAC, while strong pricing, productivity and cost control supported an 11.1% adjusted EBITA margin that would have been higher absent tariffs and FX and underpinned a marked improvement in free cash flow.
The company extended its life science offering with a new steam sterilizer for labs and research and reached key regulatory milestones, including a CE mark for its next-generation Cardiohelp II ECLS system and EU MDR approval for the Intergard Synergy vascular graft, reinforcing its positioning in critical care and cardiovascular surgery. Management reiterated its outlook for 2026, expecting 3–5% organic net sales growth despite geopolitical uncertainty and a softer pharma investment climate affecting project-based WIS orders.
The most recent analyst rating on ($SE:GETI.B) stock is a Hold with a SEK235.00 price target. To see the full list of analyst forecasts on Getinge stock, see the SE:GETI.B Stock Forecast page.
More about Getinge
Getinge is a global medical technology company that supplies equipment and solutions for acute care, surgical workflows and life science applications. Its portfolio spans ventilators, cardiovascular and extracorporeal life support (ECLS) systems, operating room equipment, infection control solutions and sterilizers, with a strong focus on recurring consumables and services.
Average Trading Volume: 712,110
Technical Sentiment Signal: Hold
Current Market Cap: SEK54.38B
Find detailed analytics on GETI.B stock on TipRanks’ Stock Analysis page.